NeuroMetrix (NSDQ:NURO) said this week that it reeled in a $3.8 million milestone payment from its collaboration with GlaxoSmithKline‘s (NYSE:GSK) consumer healthcare unit.
The strategic deal between the two groups was first announced in January this year. According to the terms of the deal, GSK acquired exclusive ownership of NeuroMetrix’s Quell pain-relief device outside the U.S., in exchange for $5 million upfront and up to $21.5 million in milestone payments.
Get the full story at our sister site, Drug Delivery Business News.
The post NeuroMetrix lands $4m milestone payment from GSK deal appeared first on MassDevice.
from MassDevice https://ift.tt/2LmhRNs
Cap comentari:
Publica un comentari a l'entrada